By Admin at 1 Jun 2016

In 2014, the FDA approved the immunotherapy drug pembrolizumab (brand name Keytruda®) for people with melanoma that cannot be removed by surgery or that has spread to other parts of the body. The drug was approved under an accelerated fast-track process because of positive initial results from a clinical trial. The end results of that study have now been released and confirm the drug’s promise for late-stage melanoma patients.

By Admin at 23 May 2016

Gateway has just approved two new immunotherapy trials. A brain cancer study at MD Anderson will assess if immunotherapy can target a virus (cytomegalovirus or CMV) that is commonly found in Glioblastoma cancer cells but not in normal brain tissue. And, a pancreatic cancer study at Johns Hopkins will assess the effectiveness of combining five treatment modalities (including the promising new drug Pembrolizumab) on patients with aggressive and deadly advanced pancreatic adenocarcinoma.